Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Insight on Incyte: This Biotech Is Running a Bevy of Drug-Development Programs

Even with some new streamlining recently crafted by the U.S. Food and Drug Administration (FDA), the pathway to new drug approvals is a long and expensive one. The Tufts Center for the Study of Drug Development recently said that it now takes a decade and a staggering $2.9 billion to bring a new drug to market.

The payoffs, of course, can be huge.

As a biotech investor, you like to find firms that are doing all they can to traverse that risk - and find a payoff.

One that we like here is Incyte Corp. (Nasdaq: INCY), a Delaware-based biotech whose shares have zoomed 50% since we brought them to you back on Christmas Eve.

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK